Amundi
ARCT icon

Amundi’s Arcturus Therapeutics ARCT Stock Holding History

Amundi’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-950
Closed -$9.01K – 1686
2025
Q1 		$9.01K Sell
950
-45
-5% -$714 ﹤0.01% 1887
2024
Q4 		$18.9K Buy
995
+54
+6% +$1.02K ﹤0.01% 1892
2024
Q3 		$21.1K Hold
941
– – ﹤0.01% 1904
2024
Q2 		$20.6K Sell
941
-720
-43% -$21.8K ﹤0.01% 1845
2024
Q1 		$43.7K Hold
1,661
– – ﹤0.01% 1854
2023
Q4 		$54.7K Hold
1,661
– – ﹤0.01% 1873
2023
Q3 		$38.1K Hold
1,661
– – ﹤0.01% 1893
2023
Q2 		$47.6K Buy
+1,661
New +$45.2K ﹤0.01% 1900
2021
Q4 		– Sell
-648
Closed -$31K – 1676
2021
Q3 		$31K Buy
+648
New +$29K ﹤0.01% 1543

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Amundi's ARCT Position: Q2 2025 in Review

Amundi sold out of Arcturus Therapeutics (ARCT) in Q2 2025, closing a stake of 950 shares — an estimated $9.01K sold.

Amundi first reported a position in ARCT in Q3 2021 and held it in 9 quarters. The position peaked at $54.7K in Q4 2023. 143 funds tracked by Wall St. Rank hold ARCT as of Q2 2025.

  • Amundi reported no remaining Arcturus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Amundi sold 950 Arcturus Therapeutics shares in Q2 2025, an estimated $9.01K.
  • Amundi first reported a position in Arcturus Therapeutics in Q3 2021 and held it in 9 quarters.
  • Amundi's Arcturus Therapeutics position peaked at $54.7K in Q4 2023.
  • 143 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2025.

Based on Amundi's 13F filing for Q2 2025, filed 13 Aug 2025.